Expression of Vascular Endothelial Growth Factor in Uveal Melanoma

A prerequisite for the growth, progression and metastasis of malignant tumors of any localization is the development of its own vascular network. Newly formed vessels not only nourish the primary tumor, but also create conditions for the spread of tumor cells through the circulatory system and the f...

Full description

Saved in:
Bibliographic Details
Published inOftalmologii͡a Vol. 18; no. 4; pp. 914 - 921
Main Authors Likhvantseva, V. G., Anurova, O. A., Astakhova, S. E., Vereshchagina, M. V., Ovanesyan, V. E., Stepanova, E. V.
Format Journal Article
LanguageEnglish
Russian
Published Ophthalmology Publishing Group 29.12.2021
Subjects
Online AccessGet full text
ISSN1816-5095
2500-0845
DOI10.18008/1816-5095-2021-4-914-921

Cover

Abstract A prerequisite for the growth, progression and metastasis of malignant tumors of any localization is the development of its own vascular network. Newly formed vessels not only nourish the primary tumor, but also create conditions for the spread of tumor cells through the circulatory system and the formation of distant metastases. Angiogenesis is able to launch a small population of tumors from 100–300 cells that have accumulated genetic aberrations and have begun to express proangigenic molecules. The phenomenon is known as “transformation of tumor cells into angiogenic phenotype”. A tumor with angiogenic phenotype carries a high potential for proliferation and malignization. This pattern has been found in many types of cancer, but studied less in uveal melanoma. Meanwhile, in this aspect, uveal melanoma, metastasizing exclusively in a hematogenic way, with its selective, organotropic nature of metastasis, becomes an attractive model for the study of the molecular “scenario” of tumor angiogenesis studies allow us to say that, UM is subject to the general patterns of the development of malignant tumors. As with many types of tumors, VEGF is an obligate condition for the development and progression of UM. The VEGF molecule’s producers in UM are two cell populations: endothelial vascular cells and tumor cells. VEGF’s expression in UM is cyclical. The cycle is re-initiated, apparently, by increasing cell density in tumor proliferate and the development of hypoxia zones. We found no correlation between the intensity of pigmentation, necrosis, hemorrhage, germination in the corner of the front chamber, ophthalmohypertension on the one hand, and expression of VEGF in UM cells on the other. At the same time, a direct link between the expression of VEGF in tumor cells and EC vessels on the one hand and the thickness, base diameter, as well as the localization of UM, on the other hand, has been revealed. Additionally, VEGF expression in tumor cells was closely correlated with the histological structure of UM, and VEGF expression in EC correlated with the stage of the disease. Thus, the authors showed that UM, like other malignant solid tumors, is prone to transformation into angiogenic phenotype and expression of VEGF.
AbstractList A prerequisite for the growth, progression and metastasis of malignant tumors of any localization is the development of its own vascular network. Newly formed vessels not only nourish the primary tumor, but also create conditions for the spread of tumor cells through the circulatory system and the formation of distant metastases. Angiogenesis is able to launch a small population of tumors from 100–300 cells that have accumulated genetic aberrations and have begun to express proangigenic molecules. The phenomenon is known as “transformation of tumor cells into angiogenic phenotype”. A tumor with angiogenic phenotype carries a high potential for proliferation and malignization. This pattern has been found in many types of cancer, but studied less in uveal melanoma. Meanwhile, in this aspect, uveal melanoma, metastasizing exclusively in a hematogenic way, with its selective, organotropic nature of metastasis, becomes an attractive model for the study of the molecular “scenario” of tumor angiogenesis studies allow us to say that, UM is subject to the general patterns of the development of malignant tumors. As with many types of tumors, VEGF is an obligate condition for the development and progression of UM. The VEGF molecule’s producers in UM are two cell populations: endothelial vascular cells and tumor cells. VEGF’s expression in UM is cyclical. The cycle is re-initiated, apparently, by increasing cell density in tumor proliferate and the development of hypoxia zones. We found no correlation between the intensity of pigmentation, necrosis, hemorrhage, germination in the corner of the front chamber, ophthalmohypertension on the one hand, and expression of VEGF in UM cells on the other. At the same time, a direct link between the expression of VEGF in tumor cells and EC vessels on the one hand and the thickness, base diameter, as well as the localization of UM, on the other hand, has been revealed. Additionally, VEGF expression in tumor cells was closely correlated with the histological structure of UM, and VEGF expression in EC correlated with the stage of the disease. Thus, the authors showed that UM, like other malignant solid tumors, is prone to transformation into angiogenic phenotype and expression of VEGF.
Author Stepanova, E. V.
Ovanesyan, V. E.
Anurova, O. A.
Likhvantseva, V. G.
Astakhova, S. E.
Vereshchagina, M. V.
Author_xml – sequence: 1
  givenname: V. G.
  orcidid: 0000-0002-3175-9592
  surname: Likhvantseva
  fullname: Likhvantseva, V. G.
  organization: A.I. Burnazyan Federal Biophysical Center of FMBA of Russia
– sequence: 2
  givenname: O. A.
  surname: Anurova
  fullname: Anurova, O. A.
  organization: National Medical Research Center for Obstetrics, Gynecology and Perinatology named after academician V.I. Kulakov
– sequence: 3
  givenname: S. E.
  surname: Astakhova
  fullname: Astakhova, S. E.
  organization: Academy of Postgraduate Education of the Federal Scientific and Clinical Cente for Specialized Medical Assistance and Medical Technologies of FMBA of Russia
– sequence: 4
  givenname: M. V.
  surname: Vereshchagina
  fullname: Vereshchagina, M. V.
  organization: Children’s City Polyclinic No. 15, Ambulatory аnd Polyclinic Center
– sequence: 5
  givenname: V. E.
  surname: Ovanesyan
  fullname: Ovanesyan, V. E.
  organization: Yegoryev Central District Hospital
– sequence: 6
  givenname: E. V.
  surname: Stepanova
  fullname: Stepanova, E. V.
  organization: Research Institute of Experimental Diagnostics and Therapy of Tumors of National Medical Research Center of Oncology named after N.N. Blokhin
BookMark eNqNkMtOwzAQRS0EEqX0H8IHBGYcO7FXCKpSKhWxoWytqWPTVCGunPD6exKKumDFYjTS1b1ncc7YcRMax9gFwiUqAHWFCvNUgpYpB46pSDX2x_GIjbgESEEJecxGh9opm7TtFgBQIiLPR-x29rmLrm2r0CTBJ8_U2reaYjJrytBtXF1Rncxj-Og2yR3ZLsSkapLVu-vjB1dTE17pnJ14qls3-f1jtrqbPU3v0-XjfDG9WaaW8wxTrVQJupQFl9IrKrkD7gnX3tFaePJcrAsnhHaqVNoKyDHPrcglCFWUQmA2Zos9twy0NbtYvVL8MoEq8xOE-GIodpWtnclc5qwHrZAKoWGtIFcyk0IXHAdkz9J7lo2hbaPzBx6C-XFrBmlmkGYGt0aY3q3p3fbb6z9bW3XU9Qa7SFX9D8I32TR_qQ
CitedBy_id crossref_primary_10_18008_1816_5095_2022_3_594_602
Cites_doi 10.1136/bjophthalmol-2020-317949
10.1001/archopht.124.10.1428
10.1634/theoncologist.9-suppl_1-2
10.3109/02713683.2010.534573
10.1136/bjo.84.7.750
10.1167/iovs.09-4739
10.1097/00008390-200008000-00006
10.1002/9780471420194.tnmc26.pub3
10.1001/archopht.120.4.466
10.1038/eye.1997.57
10.1016/0046-8177(92)90299-I
10.1210/edrv.18.1.0287
10.1016/S0161-6420(93)31470-3
10.1136/bjo.86.4.448
10.1111/1523-1747.ep12470222
ContentType Journal Article
DBID AAYXX
CITATION
DOA
DOI 10.18008/1816-5095-2021-4-914-921
DatabaseName CrossRef
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
DatabaseTitleList
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2500-0845
EndPage 921
ExternalDocumentID oai_doaj_org_article_3e3ecf0981a7490b8068535497214650
10_18008_1816_5095_2021_4_914_921
GroupedDBID 5VS
AAYXX
ALMA_UNASSIGNED_HOLDINGS
CITATION
GROUPED_DOAJ
KQ8
ID FETCH-LOGICAL-c2231-988d09d57255f8ad2e02fa1bfeab4faf24b7e449e8d89c406166c4650487d4413
IEDL.DBID DOA
ISSN 1816-5095
IngestDate Wed Aug 27 01:18:26 EDT 2025
Thu Apr 24 23:05:22 EDT 2025
Tue Jul 01 01:03:31 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
Russian
License https://www.ophthalmojournal.com/opht/about/editorialPolicies#openAccessPolicy
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2231-988d09d57255f8ad2e02fa1bfeab4faf24b7e449e8d89c406166c4650487d4413
ORCID 0000-0002-3175-9592
OpenAccessLink https://doaj.org/article/3e3ecf0981a7490b8068535497214650
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_3e3ecf0981a7490b8068535497214650
crossref_primary_10_18008_1816_5095_2021_4_914_921
crossref_citationtrail_10_18008_1816_5095_2021_4_914_921
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-12-29
PublicationDateYYYYMMDD 2021-12-29
PublicationDate_xml – month: 12
  year: 2021
  text: 2021-12-29
  day: 29
PublicationDecade 2020
PublicationTitle Oftalmologii͡a
PublicationYear 2021
Publisher Ophthalmology Publishing Group
Publisher_xml – name: Ophthalmology Publishing Group
References ref13
ref12
ref15
ref14
ref11
ref10
ref2
ref1
ref17
ref16
ref19
ref18
ref24
ref23
ref25
ref20
ref22
ref21
ref8
ref7
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref1
– ident: ref3
– ident: ref16
  doi: 10.1136/bjophthalmol-2020-317949
– ident: ref5
– ident: ref7
– ident: ref22
  doi: 10.1001/archopht.124.10.1428
– ident: ref19
  doi: 10.1634/theoncologist.9-suppl_1-2
– ident: ref24
– ident: ref25
  doi: 10.3109/02713683.2010.534573
– ident: ref23
  doi: 10.1136/bjo.84.7.750
– ident: ref20
  doi: 10.1167/iovs.09-4739
– ident: ref17
  doi: 10.1097/00008390-200008000-00006
– ident: ref13
– ident: ref15
  doi: 10.1002/9780471420194.tnmc26.pub3
– ident: ref4
– ident: ref2
– ident: ref18
  doi: 10.1001/archopht.120.4.466
– ident: ref11
  doi: 10.1038/eye.1997.57
– ident: ref8
  doi: 10.1016/0046-8177(92)90299-I
– ident: ref6
  doi: 10.1210/edrv.18.1.0287
– ident: ref9
  doi: 10.1016/S0161-6420(93)31470-3
– ident: ref21
  doi: 10.1136/bjo.86.4.448
– ident: ref12
– ident: ref10
  doi: 10.1111/1523-1747.ep12470222
– ident: ref14
SSID ssj0001511126
Score 2.168364
Snippet A prerequisite for the growth, progression and metastasis of malignant tumors of any localization is the development of its own vascular network. Newly formed...
SourceID doaj
crossref
SourceType Open Website
Enrichment Source
Index Database
StartPage 914
SubjectTerms angiogenesis
immunohystochemical analysis
markers of endothelial cells
prognosis
uveal melanoma
Title Expression of Vascular Endothelial Growth Factor in Uveal Melanoma
URI https://doaj.org/article/3e3ecf0981a7490b8068535497214650
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NSwMxEA3SQ_EifmL9IoLX0E02u0mOVlqLUE9WegvJboJC3UppxZ_vzO5a6kkPHvYSmLA8XnbeYzMzhNxo56XygbMQo2Yy9RlzqXHMy6JQyqNIwNrhyWM-nsqHWTbbGvWFd8Ka9sANcP00pKGIidHcKWkSr5McMgy4GoUjqRu3nphky0w19cEca2PQbWmeM8iKWZdc4xcCBJLubxaBJAI8FBx5eAT_kZy2evjXyWa0T_ZalUhvm7c7IDvL9SHpTtr_4EdkMPxsL7BWdBHpc3udlA6rEiuq5kAqeg8Ge_VCR_VAHfpa0ekHiEI6CXNXLd7cMZmOhk93Y9ZOQ2AFpHDOjNZlYspMgQmI2pUiJCI67mMAuKOLQnoVpDRBl9oUmKfzvECEwJKUIHrSE9KpFlU4JVR4EA2RB6dEKr3zxvNoVAIbZKEsXN4j-hsGW7StwnFixdyiZUAELSJoEUGLCFppAUELCPaI2IS-N_0y_hI0QKw3Adjyul4AItiWCPY3Ipz9xybnZLdmBBdMmAvSWS3X4RJUx8pf1QT7Avrcycc
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Expression+of+Vascular+Endothelial+Growth+Factor+in+Uveal+Melanoma&rft.jtitle=Oftalmologii%CD%A1a&rft.au=V.+G.+Likhvantseva&rft.au=O.+A.+Anurova&rft.au=S.+E.+Astakhova&rft.au=M.+V.+Vereshchagina&rft.date=2021-12-29&rft.pub=Ophthalmology+Publishing+Group&rft.issn=1816-5095&rft.eissn=2500-0845&rft.volume=18&rft.issue=4&rft.spage=914&rft.epage=921&rft_id=info:doi/10.18008%2F1816-5095-2021-4-914-921&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_3e3ecf0981a7490b8068535497214650
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1816-5095&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1816-5095&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1816-5095&client=summon